Selenium and bladder cancer risk: a meta-analysis.
BACKGROUND
Selenium is considered to be an antioxidant, and its high levels have been inversely associated with cancer risk of several sites. This meta-analysis examined the relationship between levels of selenium measured in serum and toenails, and the risk of bladder cancer.


METHODS
A meta-analysis using data from seven published epidemiologic studies (three case-control, three nested case-control, one case-cohort) published before March 2010 was done to examine the association between levels of selenium and bladder cancer. Fixed and random effects analyses were done to calculate meta-odds ratio (mOR) and 95% confidence intervals (CI). Heterogeneity among studies was measured by the I(2) statistic.


RESULTS
Overall, the risk of bladder cancer was inversely associated with elevated levels of selenium according to a random-effects model (mOR = 0.61; 95% CI, 0.42-0.87). The mORs were 0.95 (95% CI, 0.69-1.27) and 0.55 (95% CI, 0.32-0.95) among men and women, respectively. Sex, type of sample specimen, smoking status, and study design were found to be potential sources of heterogeneity.


CONCLUSIONS
A significant protective effect of selenium, observed mainly among women, may result from gender-specific differences in its accumulation and excretion. The heterogeneity found among studies was mainly linked to the different biological sample specimens used to measure the selenium concentrations and the small size of the studies. Although these results suggest a protective effect of selenium for bladder cancer risk, additional large studies are warranted to support these preliminary evidence.


CONCLUSIONS
The present results suggest a beneficial effect of high selenium intake for bladder cancer risk.
Amaral
André F S
AF
Spanish National Cancer Research Centre, Genetic and Molecular Epidemiology Group, Madrid, Spain.
Cantor
Kenneth P
KP
Silverman
Debra T
DT
Malats
Núria
N
D005260:Female; D006801:Humans; D008297:Male; D009262:Nails / Q000378:metabolism; D012307:Risk Factors; D012643:Selenium / Q000097:blood / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000378:metabolism*
D012643:Selenium
Environ Res. 2006 Sep;102(1):125-39
16442520
Cancer Causes Control. 2005 Nov;16(9):1125-31
16184479
BJU Int. 2003 May;91(7):608-12
12699469
Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):718-26
18827575
Anticancer Res. 2004 May-Jun;24(3a):1401-8
15274301
Ann Epidemiol. 2006 Jan;16(1):53-8
15961316
Eur J Clin Nutr. 2004 Mar;58(3):391-402
14985676
Biometals. 2004 Oct;17(5):567-8
15688865
Lancet. 2005 Aug 20-26;366(9486):649-59
16112301
Am J Clin Nutr. 1990 Nov;52(5):858-62
2239761
Int J Urol. 2006 Sep;13(9):1180-4
16984549
Br J Cancer. 2005 Oct 3;93(7):804-6
16175184
Cancer Prev Res (Phila). 2009 Jan;2(1):70-3
19139020
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004183
18677777
Stat Med. 2002 Jun 15;21(11):1539-58
12111919
Am J Epidemiol. 1991 Aug 15;134(4):356-61
1877596
Epidemiology. 1996 Jul;7(4):384-90
8793364
Cancer Causes Control. 2007 Feb;18(1):7-27
17186419
Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):771-8
15159309
Int J Cancer. 2005 Aug 20;116(2):182-6
15800922
Chem Biol Interact. 2006 Mar 10;160(1):1-40
16430879
Am J Clin Nutr. 1991 May;53(5):1288-94
2021136
Am J Clin Nutr. 2006 Oct;84(4):762-73
17023702
World J Urol. 2007 Jun;25(3):285-95
17530260
Cancer Res. 1989 Nov 1;49(21):6144-8
2790827
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1505-6
12433737
JAMA. 2009 Jan 7;301(1):39-51
19066370
Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493-7
8220096
Mayo Clin Proc. 2008 Jan;83(1):23-34
18173999
Br J Nutr. 2006 Feb;95(2):313-20
16469147
Cell Mol Life Sci. 2000 Dec;57(13-14):1864-73
11215513
Sci Total Environ. 2010 Feb 1;408(5):1014-20
20018346
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1292-7
12433705
J Natl Cancer Inst. 1987 Jul;79(1):103-8
3474437
Eur J Clin Chem Clin Biochem. 1995 Mar;33(3):127-33
7605824
Cancer Lett. 2008 Feb 8;259(2):218-30
18054426
Anticancer Res. 2006 Mar-Apr;26(2A):899-904
16619485